Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation

Completed · Phase 3

Conditions studied: Cancer

In brief

RATIONALE: Antivirals such as valacyclovir act against viruses and may be effective in preventing cytomegalovirus. It is not yet known if valacyclovir is effective in preventing cytomegalovirus in patients undergoing stem cell transplantation. PURPOSE: Randomized phase III trial to determine the effectiveness of valacyclovir in preventing cytomegalovirus in patients who are undergoing donor stem cell transplantation.

Key facts

Study ID

NCT00045292

Run by

Fred Hutchinson Cancer Center

Starts

2002-04-01

Expected to finish

2004-10-01

Last updated by the study team

2010-09-21

Who can join

Age: 12 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• City of Hope Comprehensive Cancer Center — Duarte, California, United States
• Stanford Cancer Center at Stanford University Medical Center — Stanford, California, United States
• UNMC Eppley Cancer Center at the University of Nebraska Medical Center — Omaha, Nebraska, United States
• Baylor University Medical Center — Dallas, Texas, United States
• Huntsman Cancer Institute — Salt Lake City, Utah, United States
• Fred Hutchinson Cancer Research Center — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.